Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer. Dr. Benaim has more than 25 years of healthcare experience, including 15 years of clinical research experience in academia, government and pharmaceutical industry, as well as extensive experience in global regulatory affairs. Dr. Benaim previously served as Chief Medical Officer at Rexahn Pharmaceuticals, where he was responsible for leading clinical development programs, and providing strategic and clinical guidance. Prior to joining Rexahn, he held senior leadership positions at Berg Pharma, Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals Company and Sangamo BioSciences, Inc. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas, and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude’s Children’s Research Hospital, in Memphis, Tennessee.